Browse Drug Recalls
16 FDA drug safety recalls.
FDA Drug Recall Enforcement Database
Browse 16 FDA drug recall enforcement actions. Each entry includes the product description, reason for recall, classification (Class I through III based on severity), recalling firm, and distribution details. Use the filters below to search by year, classification, state, or keyword.
Drug Safety Recalls
Browse 16 FDA drug recalls.
| Date | Product | Reason | Class | Firm |
|---|---|---|---|---|
| May 19, 2023 | Nafcillin for Injection, USP, 1 gram per vial, Rx only, Mfd. for SAGENT Pharm... | Lack of Assurance of Sterility | Class II | Sagent Pharmaceuticals Inc |
| May 19, 2023 | Nafcillin for Injection, USP, 2 gram per vial, Rx only, Mfd. for SAGENT Pharm... | Lack of Assurance of Sterility | Class II | Sagent Pharmaceuticals Inc |
| May 19, 2023 | Nafcillin for Injection, USP, 10 gram per Pharmacy Bulk Package, Rx only, Mfd... | Lack of Assurance of Sterility | Class II | Sagent Pharmaceuticals Inc |
| Feb 28, 2023 | Heparin Sodium Injection, USP, 20,000 USP units per mL, 25 x 1 mL Multi-Dose ... | Labeling: Not elsewhere classified | Class II | Sagent Pharmaceuticals Inc |
| Mar 11, 2021 | Phenylephrine HCl Injection, USP, 10 mg per mL, 1 mL per Single-Dose Vial pac... | Lack of Assurance of Sterility: customer complaints of loose crimped vial overseals which may res... | Class II | Sagent Pharmaceuticals Inc |
| Apr 30, 2019 | Ketorolac Tromethamine Injection, USP, 60 mg per 2 mL (30 mg per mL), 2 mL V... | Lack of Sterility Assurance: Microbial growth detected during a routine simulation of the manufac... | Class II | Sagent Pharmaceuticals Inc |
| Mar 5, 2018 | methylPREDNISolone Sodium Succinate for Injection, USP, 125 mg* per vial, Sin... | Failed Impurities/Degradation Specifications: High out of specification results for an impurity. | Class II | Sagent Pharmaceuticals Inc |
| Mar 5, 2018 | methylPREDNISolone Sodium Succinate for Injection, USP, 1 gram* per vial, Sin... | Failed Impurities/Degradation Specifications: High out of specification results for an impurity. | Class II | Sagent Pharmaceuticals Inc |
| Mar 5, 2018 | methylPREDNISolone Sodium Succinate for Injection, USP, 40 mg* per vial, Sing... | Failed Impurities/Degradation Specifications: High out of specification results for an impurity. | Class II | Sagent Pharmaceuticals Inc |
| Jun 13, 2016 | Oxacillin for Injection, USP, 10 grams per pharmacy bulk package, Buffered - ... | Presence of Particulate Matter; The firm received two product complaints for small, dark particul... | Class II | Sagent Pharmaceuticals Inc |
| Mar 1, 2016 | Fluconazole Injection, USP (in 0.9% Sodium Chloride), 200 mg per 100 ml, Sing... | Cross contamination with other products: metronidazole | Class II | Sagent Pharmaceuticals Inc |
| Feb 23, 2015 | Atracurium Besylate Injection, USP, 50 mg per 5 mL (10 mg per mL), Rx Only, 5... | Lack of Assurance of Sterility: Recall initiated due to FDA observations pertaining to aseptic an... | Class II | Sagent Pharmaceuticals Inc |
| Feb 23, 2015 | Atracurium Besylate Injection, USP, 100 mg per 10 mL (10 mg per mL), Rx Only,... | Lack of Assurance of Sterility: Recall initiated due to FDA observations pertaining to aseptic an... | Class II | Sagent Pharmaceuticals Inc |
| Oct 3, 2014 | Ketorolac Tromethamine INJECTION, USP, 30 mg per mL, a) 1 mL vial (NDC 25021-... | Incorrect or Missing Lot and/or Exp Date: Ketorolac Tromethamine Injection, is being recalled as... | Class II | Sagent Pharmaceuticals Inc |
| Mar 4, 2014 | Zoledronic Acid Injection 5 mg per 100 mL (0.05 mg/mL), 100 mL single-use bag... | Lack of Assurance of Sterility; leaking of premix bags | Class II | Sagent Pharmaceuticals Inc |
| Jun 7, 2013 | VECURONIUM Bromide for Injection, 10 mg* per vial, *1 mg per mL when reconsti... | CGMP Deviations: product was not manufactured under current good manufacturing practices which co... | Class II | Sagent Pharmaceuticals Inc |
Frequently Asked Questions
When a drug safety issue is identified — through FDA inspections, laboratory testing, adverse event reports, or manufacturer quality checks — the responsible company issues a recall to remove the affected products from the market. Pharmacies pull the product from shelves, and consumers are advised to contact their healthcare provider for alternatives.
The leading causes include cGMP deviations, impurity contamination (including nitrosamines like NDMA), failed dissolution or stability testing, sterility issues, potency problems, labeling errors, and foreign particle contamination.
Use the search and filter tools on this page to look up specific medications, active ingredients, or manufacturers. Each recall entry includes the product description, lot numbers, and distribution details.